Background
Pfizer Inc. holds U.S. Patent No. 9,492,559, which covers pneumococcal vaccine compositions containing a Streptococcus pneumoniae serotype 22F glycoconjugate with a molecular weight between 1,000 kDa and 12,500 kDa. Pneumococcal vaccines protect against bacterial infections that cause pneumonia, meningitis, and ear infections, and they represent a major commercial product line in the vaccine industry. Sanofi Pasteur and other parties challenged the patent in inter partes review proceedings, arguing that the claimed molecular weight range was obvious.
The Patent Trial and Appeal Board (PTAB) agreed, concluding that glycoconjugate molecular weight is a “result-effective variable” — a parameter that is known to affect a desired outcome — and that a skilled artisan would have been motivated to optimize it. PTAB found the claimed range obvious as the result of routine optimization. Pfizer challenged the PTAB’s application of the result-effective variable doctrine, arguing in part that the doctrine should not apply because the prior art did not disclose any specific molecular weight range that overlaps with the claimed range.
The Court’s Holding
The Federal Circuit affirmed PTAB’s obviousness finding but vacated and remanded the denial of Pfizer’s motion to amend certain claims for further proceedings. On the central obviousness question, the court addressed an important doctrinal question: does the result-effective variable doctrine require that the prior art disclose an overlapping range before a skilled artisan would be motivated to optimize a parameter?
The court answered no. The result-effective variable doctrine holds that when a prior art parameter is known to affect a desired result, a skilled artisan would be motivated to optimize that parameter — and the existence of a claimed range covering the optimal value becomes prima facie obvious. The Federal Circuit clarified that this doctrine can apply even when there is a gap between what the prior art discloses and what the claims cover — meaning even when the prior art does not explicitly disclose a range that overlaps with the claimed range. If the prior art establishes that a parameter is known to be result-effective, skilled artisans would explore it through routine experimentation, and a claim covering the optimal values within that exploration may be obvious without the need for an exact prior art range to overlap with the claimed values.
The court also emphasized that the optimization analysis is holistic: the motivation to optimize must be viewed through the lens of what a person of ordinary skill in the art would do given the state of the art, and it regularly involves combining references while retaining a reasonable expectation of success. PTAB’s conclusion that molecular weight was known to affect vaccine stability and immune response — making it a recognized result-effective variable — was supported by substantial evidence.
Key Takeaways
- The result-effective variable doctrine can render a claimed range obvious even when prior art does not disclose an overlapping range — the doctrine applies whenever the prior art establishes that the parameter is known to affect a desired result.
- Routine optimization of known result-effective variables can support an obviousness finding even when the specific claimed range was not explicitly tested or disclosed in the prior art.
- Pharmaceutical and biotech patent applicants claiming specific numerical ranges should invest in data showing the claimed range produces results that would be unexpected or non-obvious given what was known about the parameter — not just data showing the claimed range works.
- The decision expands the reach of obviousness challenges to chemical and biological patents claiming specific ranges of known parameters, particularly in drug formulation, vaccine development, and similar arts.
Why It Matters
This decision meaningfully expands the practical scope of the result-effective variable doctrine, which has become an important tool for generic and biosimilar companies challenging pharmaceutical and biotech patents. Previously, there was some uncertainty about whether the doctrine required the prior art to disclose a range that overlaps or is adjacent to the claimed range. By clarifying that no such overlap is required, the Federal Circuit makes it easier to argue that claimed ranges are obvious through routine optimization whenever the underlying parameter is a known result-effective variable.
For vaccine developers and other biotech companies, the ruling signals that patents claiming specific molecular weight ranges, concentration ranges, pH ranges, or similar parameters for compounds known to have those properties recognized as result-effective face significant obviousness exposure in IPR proceedings. Companies seeking to protect such innovations should build their specifications and prosecution records with experimental evidence demonstrating that the claimed range produces results that were not predictable from the prior art — that the claimed range is critical or produces unexpected advantages compared to adjacent ranges — rather than simply showing that the claimed range works.